Patrick Volkert Jozef Johannes Vink
Independent DirectorDr. Patrick Volkert Jozef Johannes Vink, M.D., serves as Non-Executive Deputy Chairman & Senior Independent Director since July 2026 and as Director since July 7, 2026 at Avacta Group Plc. He serves as Chairman of the Board of Directors at Arch Biopartners Inc. since January 15, 2026; he also served the company as Director from December 12, 2016 to November 2019 and has served as Strategic Advisor since 2019. Dr. Vink serves as Chairman of Secura Bio, Inc. since July 2025. He served as Lead Independent Director at Spero Therapeutics, Inc. since August 1, 2023 until November 10, 2026, where he also served as Independent Director from September 2015 to August 1, 2023. Dr. Vink serves as an Independent Director of SQZ Biotechnologies Company since July 2021 and as Chairman of the Board at Biognosys AG since June 2020. He has served as Chairman of the Board at F2G Ltd since April 8, 2019 and as an Independent Non-Executive Director of Amryt Pharma plc since September 24, 2019. Dr. Vink is a Senior Advisor at Athyrium Capital Management, LP, which he joined in 2019 and focuses on Private Debt. He is also Operating & Advisory Partner of Gyrus Capital S.A., Venture Partner of Forbion Capital Partners B.V., Managing Partner of Galenus Capital, Chairman of Micreos NV and also served as Director of Spero Therapeutics, LLC since September 2015 until November 10, 2026. Additionally, he serves as a Non-Executive Director of Micreos BV, Director of Piqur AG and Director of Santhera Pharmaceuticals Ag/Santhera AG. Previously, Dr. Vink served as Non-Executive Independent Director of Santhera Pharmaceuticals Holding AG from April 4, 2017 to 2023. He was Executive Chairman of Circio Holding ASA until April 29, 2020 and had served as Chairman of the Board from November 30, 2017. He was Independent Non-Executive Chairman of Acacia Pharma Group plc from 2016 to April 7, 2020 and Chairman of the Board of Directors of Targovax Oy/Targovax ASA from October 2017 to April 2020. Dr. Vink was an Independent Director of ADVANZ PHARMA Corp. Limited from March 24, 2016 to September 6, 2018. He served as Venture Partner of VI Partners AG from 2018, where he focused on Healthcare. He was COO & Executive VP of Cubist Pharmaceuticals LLC from January 1, 2015 to April 2015; prior to this, he was General Manager of International Business at Cubist Pharmaceuticals Inc. from September 2012 to January 1, 2015, where he was responsible for all business activities in international markets outside the USA. He joined the firm in September 2012 and also served as Senior Vice-President and Head of all International Business Operations until January 1, 2015. Dr. Vink was Chairman of the Board of Directors of NMD Pharma A/S from 2015 and Director of Inhibikase Therapeutics, Inc. from May 4, 2015. He served as Senior Vice President, Global Head of Hospital Business and Global Head of Biologics for Mylan N.V./Mylan Inc. from February 2008 to September 2012, where he coordinated all hospital business. He joined Mylan in 2008 and established its operations in Switzerland. He also served as Global Head of Biologics and Senior Vice President of Viatris Inc., which he joined in February 2008. Dr. Vink was Head of Business Franchise Biopharmaceuticals of Sandoz International GmbH from November 2002 to January 2006 and Head of Global Business Franchise Biopharmaceuticals at Novartis Generics, Sandoz from May 2003. He served as Vice President of International at Biogenidec Inc. from 2000 to 2002, Vice President of Sales International at Biogen from 2000 to 2002 and Regional Director of Central Europe at Biogen from 2000. He also held roles as Vice-President International Business for Biogen, Inc. and Vice-President International operations at Biogen. He was Head of Worldwide Marketing, Cardiovascular and Thrombosis for Sanofi-Synthélabo SA/Sanofi-Synthelabo Ltd. from 1997 to 2000 and Vice President of Strategic Marketing Cardio-Thrombosis at Sanofi-Synthelabo from November 1997 to July 2000. He was General Manager of Nutricia Hungary from 1995 and served as Commercial Director of Sanofi Netherlands from 1988 to 1995. He was also a Senior Advisor of INKEF Netherlands Manager B.V. and served as a Senior Advisor, Operational Director and Senior Director at INKEF Capital. He has several years' experience in the biopharmaceutical industry. During his career, he has been involved in initial public listings, achieving meaningful development, regulatory and commercial milestones as well as geographic expansions. With a proven track record of building and growing businesses through positions spanning operations, commercial and R&D, he has led worldwide teams to drive product development and commercialization across a number of therapeutic areas. He has also been an advisor to the pharmaceutical industry since 2015. He has an M.B.A. in Business Management from the University of Rochester - William E. Simon Graduate School of Business Administration in 1992 and an M.D. in Medicine from Universiteit Leiden in 1988.
Positions
- Company NameSQZ Biotechnologies CompanyStock CodeSQZBPositionIndependent DirectorColleagues
- LJLawrence J. KnopfGeneral Counsel & Secretary
- RSRobert S. LangerCo-Founder & Member of Scientific Advisory Board
- MSMarshelle Smith WarrenChief Medical Officer
- IRIpsita RoymoulikSenior Vice President of CMC & QUALITY
- MSMarc SchegerinIndependent Director
- KFKlavs F. JensenIndependent Director
- AWAmy W. SchulmanDirector
